BASEL, Switzerland, Jan. 30, 2019 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced the appointments of Sandip Kapadia and Patrick…
BASEL, Switzerland, Jan. 16, 2019 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced that the U.S. Food…
BASEL, Switzerland, Jan. 8, 2019 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced that it has appointed…
BASEL, Switzerland, Nov. 29, 2018 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating the root causes of rare conditions, today announced that the European Commission has granted Orphan Drug Designation…
BASEL, Switzerland, Oct. 9, 2018 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating root causes of rare conditions, today announced the acquisition of GLyPharma Therapeutic Inc. (“GLyPharma”) for…
